IFPMA and WADA to cooperate in the fight against doping in sport
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and the World Anti-Doping Agency (WADA) signed a Joint Declaration on Cooperation in the Fight against Doping in Sport today in Lausanne, Switzerland. The Declaration was signed by Mr. David Howman, Director General of WADA, and Mr. Haruo Naito, President of the IFPMA and President and...
Read moreExpanded code of practice for pharmaceutical industry updates ethical and professional standards for interactions
Code extended to cover all interactions with healthcare professionals, medical institutions, and patient organizations Code provides effective framework for ethical business practices International patient organization welcomes new rules IFPMA encourages equally high standards across healthcare sector 1 March 2012, Geneva – Today the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) announced an expansion of...
Read moreIFPMA, BIO and WADA advance anti-doping collaboration with the launch of 2 Fields 1 Goal campaign
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the global Biotechnology Industry Organization (BIO) and the World Anti-Doping Agency (WADA) today announced the launch of the 2 FIELDS 1 GOAL: Protecting the Integrity of Science and Sport campaign, that aims to achieve the goals of the Joint Declaration on Cooperation in the Fight against...
Read moreExpanded IFPMA Code of Practice for pharmaceutical industry goes into effect around the world
Code covers all interactions with healthcare professionals, medical institutions, and patient organizations Code provides effective framework for ethical business practices Company and association members of IFPMA adopt updated standards Today the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) announced that its expanded Code of Practice is in effect around the world. Governing how companies...
Read moreIFPMA supports the Coalition for Epidemic Preparedness Innovation launched at WEF17 in Davos
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) supports the aims of a newly formed public-private partnership to accelerate research and development of vaccines for emerging infectious diseases. The Coalition for Epidemic Preparedness Innovation (CEPI) is a direct response to calls from four independent expert reports into the Ebola epidemic for a new system...
Read moreR&D-based biopharmaceutical industry welcomes UN Declaration on TB Partnerships are key to foster innovation and access
Geneva, 26 September 2018 – Today, at the first-ever United Nations (UN) High-Level Meeting on Tuberculosis (TB), world health leaders agreed on a new, collaborative, focused, and forward-looking declaration that sets priorities for the global fight against TB. Recognizing the complexity of the disease and the barriers to progress, the declaration aims to improve access...
Read more11th annual G-FINDER report shows consistent growth of the biopharmaceutical industry investment in neglected diseases
Geneva, 23 January 2019: IFPMA, the global R&D biopharmaceutical industry association, welcomes the 11th G-FINDER report[i] which tracks public, private and philanthropic investment into product R&D for neglected diseases, which predominantly affect the developing countries. As with previous years, the report shows Bio-pharmaceutical industry investment as the third largest funder, after the USA’s National Institutes...
Read moreIFPMA and WHO Global Research and Innovation Forum
IFPMA and WHO Global Research and Innovation Forum IFPMA as the body representing the innovator biopharmaceutical industry in official relations with the UN, together with a number of its member companies were invited to the WHO Global Research and Innovation Forum on COVID-19 which took place on 11 and 12 February 2020 in Geneva. IFPMA...
Read morePharma Statement for The Coronavirus Global Response Pledging Marathon
Indianapolis/Brussels, 4 May 2020 Statement delivered by: David Ricks, President of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and CEO of Eli Lilly (2 minutes) Greeting: My name is Dave Ricks. As the Chairman of IFPMA, the International Federation of Pharmaceutical Manufacturers and Associations, and as CEO of Lilly, I am pleased to...
Read moreIFPMA Statement to G20 Health and Finance Ministers
Geneva, 17 September 2020: Now more than ever, the adage “Health is Wealth” has heightened significance, with the COVID-19 pandemic highlighting the delicate and essential interdependence between public health and economic prosperity. The biopharmaceutical industry is working alongside governments worldwide to combat the burden of this unprecedented crisis, recognizing that unparalleled collaboration among all sectors...
Read more